Group 1: Product Matrix and Market Position - The company has established a clear and advantageous external product matrix, with significant exclusive and medical insurance advantages in key varieties. Approved products include: Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, Anti-inflammatory Pain Relief Patch, Lidocaine Gel Patch, Strong Waist and Bone Strengthening Patch, and Daiwen Moxibustion Patch [2] - The Ketoprofen Gel Patch is a key exclusive product with significant market competitiveness, while the Daiwen Moxibustion Patch holds both traditional Chinese medicine exclusivity and medical insurance exclusivity, showcasing distinct advantages [2] Group 2: Brand Development Strategies - The company has implemented a series of systematic and innovative measures to enhance brand influence and market recognition, including expanding into retail pharmacies and online platforms [3] - A brand upgrade event was held on December 6, 2025, introducing the "JiuDian Pain Relief Expert" symbol and the slogan "Change to JiuDian for Pain Relief Patches," aimed at addressing consumer pain points and enhancing brand communication and market competitiveness [3] Group 3: Sales and Procurement Expectations - The 11th batch of national centralized procurement results will be executed nationwide starting February 2026, with procurement cycles lasting until December 31, 2028 [3] - The company is optimistic about the market prospects for the Ketoprofen Gel Patch, which was approved for listing in 2023 and successfully entered the national medical insurance directory [3] Group 4: Innovation in Drug Development - The company is undergoing a comprehensive transformation towards innovative drug research and development, utilizing a strategy of multiple R&D centers and various drug forms [4] - Two innovation drug R&D centers are being established in central and Yangtze River Delta regions, leveraging local clinical resources and cost advantages [4] - The company is focusing on various tumor and chronic disease indications, employing small molecule drugs, peptide drugs, PDC, and ADC formats [4] Group 5: New Drug Advantages - The newly introduced small molecule pain relief innovative drug YJ2301 is designed to overcome limitations of existing neurogenic pain medications, such as limited efficacy and significant side effects [4] - Clinical pre-research data for YJ2301 shows superior pain relief effects and the potential to address issues like drowsiness and tolerance, providing a new solution for neurogenic pain management [4]

12月12日，"膏药大王"九典制药（300705）发布公告，为丰富产品管线并推动创新药转型，公司将斥资 不超过4亿元引进在研镇痛新药技术。 公司于2025年12月11日召开董事会，决定与苏州缘聚医药科技有限公司签署关于小分子镇痛药物 YJ2301项目的《专利及技术转让协议》，引进相关专利及技术。此次交易的转让费用总金额不超过4亿 元，支付方式采用里程碑与销售提成的方式。 根据公告，里程碑费用不超过1100万元，由公司按项目进度向苏州缘聚支付。交易标的为苏州缘聚所拥 有的YJ2301项目的全球所有权及相关知识产权，项目已完成部分临床前研究并提交相关专利申请。 九典制药表示，此次引进旨在补充公司研发管线，增强创新研发能力与长期核心竞争力。该交易预计不 会对公司近期生产经营与财务状况产生重大影响。 然而，该领域的竞争正日趋激烈。米内网数据显示，目前已有40余家药企就洛索洛芬钠凝胶贴膏/贴剂 按新注册分类申报生产或临床，其中北京泰德制药、江苏万高药业、乐明药业、南京海纳医药、华润三 九等十余家企业的产品已获批生产并视同通过一致性评价。 竞品不断涌入，九典制药的销售压力明显加剧。财务数据显示，今年前三季度，公司期间费用 ...

证券日报网12月8日讯九典制药（300705）在12月8日回答调研者提问时表示，酮洛芬凝胶贴膏于2023年 获批上市，并成功进入国家医保目录，是国内首仿上市的独家品种，公司对其市场前景持乐观态度。公 司已经制定了新的销售策略，重点加大对院外市场的资源投入，同时强化对内部销售团队的考核力度。 ...

证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转 02 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2025-28 | | □分析师会议 特定对象调研 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 其他 | | 参与单位名称及 | 深圳晋合投资、汇智融达基金、湖南三十九铺投资者代表共 3 | | 人员姓名 人 | | | 时间 2025 | 年 12 月 8 日上午 10:00-11:30 | | 地点 | 公司会议室 | | 上市公司接待人 | 副总经理兼董事会秘书：曾蕾 | | 员姓名 | | | | 首先董事会秘书简要介绍了公司的基本情况，接下来主要采 | | | 用解答投资者提问的方式进行，主要问题回复如下： | | | 1、洛索洛芬钠凝胶贴膏集采落地后，公司有哪些具体应对措 | | 施？ | | | | 回复：洛索洛芬钠凝胶贴膏作为公司重点产品，其集采 | | | 落地后，公司将通过多维举措积极应对：在销售端，我们将 | | 投资者关系活动 | 依 ...

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received approval for clinical trials of Ketoprofen Gel Patch from the National Medical Products Administration (NMPA) [1][2] Group 1: Clinical Trial Approval - The drug name is Ketoprofen Gel Patch, with the notification number 2025LP03166, and it is classified as a Class 3 chemical drug [2][3] - The approved indications include pain relief and anti-inflammatory treatment for conditions such as osteoarthritis, shoulder periarthritis, tendonitis, tennis elbow, muscle pain, and post-injury swelling and pain [1][3] Group 2: R&D Investment - Fuyuan Pharmaceutical has invested approximately RMB 3.9676 million (about 0.4 million USD) in the research and development of the Ketoprofen Gel Patch [3] Group 3: Market Situation - As of 2024, the sales revenue of Ketoprofen Gel Patch in China is approximately RMB 49.58 million (about 4.96 million USD), with significant sales in urban public hospitals and county-level public hospitals [6] - In the first half of 2025, the sales revenue increased to approximately RMB 76.44 million (about 7.64 million USD) [7] Group 4: Regulatory Pathway - The clinical trial application has been approved, and the product must undergo clinical research and receive further approval from the NMPA before it can be marketed [7]

福元药业申请药物临床试验的酮洛芬凝胶贴膏，适应症为适用于下列疾病和症状的镇痛及消炎：骨关节 炎、肩周炎、肌腱及肌腱炎、肌腱周围炎、肱骨外上髁炎(网球肘等)、肌肉痛、外伤后肿胀及疼痛。给 药途径为局部，注册分类属化学药品3类。截至目前，福元药业对本品已投入研发费用约人民币396.76 万元(未经审计)。 智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司全资子公司福元药业有限公司(简称"福元 药业")收到了国家药品监督管理局核准签发的酮洛芬凝胶贴膏的《药物临床试验批准通知书》。 ...

Core Points - The clinical trial for Ketoprofen gel patch, aimed at alleviating knee osteoarthritis pain, has been initiated by Beijing Sunshine Novo Pharmaceutical Research Co., Ltd. and Beijing Bai'ao Pharmaceutical Co., Ltd. [1] - The trial is a multicenter, randomized, positive drug and placebo-controlled Phase III study, with a registration number of CTR20254424, first published on November 24, 2025 [1]. - The primary endpoint of the trial is the change in VAS pain score (walking) on day 29 compared to baseline, with secondary endpoints including VAS pain scores on days 15 and 22, as well as modified WOMAC scores [1]. Summary by Sections Clinical Trial Details - The trial is currently ongoing and has not yet recruited participants, with a target enrollment of 420 individuals [2]. - The drug is administered as a patch, with a dosage of one patch twice daily for four consecutive weeks [1]. Drug Information - Ketoprofen gel patch is a chemical drug indicated for knee osteoarthritis, characterized by symptoms such as knee pain, swelling, and stiffness [1]. - Diagnosis relies on symptoms, physical examination, and imaging studies like X-rays and CT scans [1]. Evaluation Metrics - The trial will evaluate the efficacy of the drug against placebo and a positive control, as well as assess the safety of the drug [1]. - Key metrics include changes in pain scores and overall functionality as measured by the WOMAC scale [1].

Group 1: Company Performance and Market Strategy - The overall business operation in Q4 is stable, with sales proceeding as planned amidst steady market demand [2][3] - The company is implementing multi-faceted measures to address the impact of the centralized procurement of Loxoprofen Sodium Gel, focusing on expanding the outpatient market and enhancing brand development [2][3] - The company has a professional OTC team of over 200 people to drive online and offline channel development, effectively broadening market coverage [7] Group 2: Innovation and R&D Focus - The company is fully transitioning to focus on innovative drug development, with a core emphasis on chemical and traditional Chinese medicine innovations [4] - In 2025, the estimated R&D expenditure is projected to be between 250 million to 300 million CNY [6] - The company is pursuing a dual approach of independent R&D and project acquisition to enhance its innovation pipeline [4] Group 3: Product Launch and Sales Expectations - The Ketoprofen Gel was approved for market entry in 2023 and is optimistic about its market prospects as it is the first generic product listed in the national medical insurance directory [5] - The company is intensifying resource allocation towards the outpatient market and strengthening internal sales team assessments to boost sales performance [5][7] Group 4: Market Challenges and Strategic Adjustments - The company acknowledges pressure on achieving annual targets due to market challenges but is committed to promoting new products and enhancing market penetration [7] - Strategies include optimizing product positioning and increasing brand influence to expand market share [7]

Group 1: Strategic Focus and Innovation - The company is fully transforming to focus on innovative drug research and development, with a core direction in chemical and traditional Chinese medicine innovation [2] - Key therapeutic areas include pain management, focusing on peptide and small molecule drugs, and oncology, with a focus on PDC drug development [2] - The company employs a dual approach of independent research and project acquisition to build core technological barriers and accelerate innovation results [3] Group 2: Product Launch and Market Expectations - The ketoprofen gel patch was approved for market launch in 2023 and has entered the national medical insurance directory, being the first generic product in the market [4] - The company has optimistic market expectations for the ketoprofen gel patch and has developed new sales strategies focusing on external markets [4] Group 3: Research and Development Investment - The estimated R&D expenditure for 2025 is projected to be between 250 million and 300 million yuan [5] Group 4: Employee Incentives and Governance - The company is implementing a share repurchase plan to support future equity incentive plans, aiming to enhance governance and align interests among stakeholders [6] Group 5: New Product Highlights - The newly introduced innovative drug JIJ02 gel has broad-spectrum antibacterial properties, low cost, and is expected to have significant market competitiveness [7][8] - JIJ02 gel is anticipated to complete Phase I clinical trials by mid-next year and will initiate Phase II trials thereafter [8] Group 6: Pricing and Procurement - The company is currently in the bidding phase for the 11th batch of national drug procurement, with submission of application materials and public pricing information due by October 21 [8]

Core Viewpoint - Tianfeng Securities report indicates that JiuDian Pharmaceutical achieved a net profit attributable to shareholders of 291 million yuan in the first half of 2025, representing a year-on-year increase of 2.57% [1] - The company is expected to benefit from the increasing demand for transdermal drug delivery and the aging population, which will support its external preparation segment [1] Financial Performance - In the second quarter of 2025, JiuDian Pharmaceutical reported a net profit of 166 million yuan, reflecting a year-on-year growth of 4.54% [1] - The performance growth in the first half of the year met expectations [1] Product Development - As of the first half of 2025, the company holds seven registered external preparation drug certificates and has over 20 external preparation products in development [1] - Key products include Loxoprofen Sodium Gel Patches, Ketoprofen Gel Patches, Anti-inflammatory Pain Relief Plasters, Lidocaine and Prilocaine Cream, and Clotrimazole Vaginal Tablets [1] Strategic Focus - The company is focusing on the innovation of chemical and traditional Chinese medicine drugs, with a core development direction in chemical drug innovation [1] - The primary research areas include pain management (focusing on peptide and small molecule drugs) and oncology (with a focus on PDC drug development) [1] Market Outlook - With the gradual launch of new products and external environmental drivers, the company is expected to maintain sustainable growth in its external preparation segment [1] - Based on changes in the competitive landscape for Loxoprofen Sodium Gel Patches, the profit forecast has been adjusted while maintaining a "Buy" rating [1]